《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2015年 > 11期

血清中期因子水平与糖尿病视网膜病变的相关性研究

来自:中国糖尿病杂志  编辑:徐清田 马宁 成兴波|点击数:|2016-02-28

      【摘要】 目的探讨血清中期因子(Midkine)与DR的相关性。 方法   选取T2DM患者90例,分为T2DM不伴DR(NDR)组30例、T2DM伴非增殖期DR(BDR)组30例和T2DM伴增殖期DR(PDR)组30例。另选体检健康者30名作为健康对照(NGT)组,经75 g OGTT排除糖尿病。检测各组FPG、HbA1c和血脂等指标,ELISA检测血清Midkine浓度。 结果    T2DM各组血清Midkine水平均高于NGT组,Midkine水平由低到高依次为NGT<NDR<BDR<PDR组[(0.43±0.29)vs(1.73±0.25)vs(3.01±1.82)vs(4.82±3.62)pg/ml,P<0.05或P<0.01]Pearson相关性分析结果显示,血清Midkine水平与DR病程、UAlb呈正相关(r=0.559、0.374,P<0.01)。多元逐步回归分析结果显示,DR病程为
血清Midkine水平的独立影响因素(β=0.375,P<0.01)。 结论   血清Midkine水平与DR病程、DR严重程度密切相关,Midkine可能参与了DR发生发展,与DR关系密切。
      【关键词】 血清中期因子;糖尿病视网膜病变;糖尿病,2型

      【Abstract】 Objective    To investigate the correlation between serum midkine and diabetic retinopathy (DR). Methods   90 T2DM were divided into four groups:T2DM patients Without DR (NDR group,n=30),T2DM patients with background DR(BR group,n=30),T2DM patients with proliferative DR (PDR group,n=30).Healthy subjects in routine examination were selected as normal control(NGT group,n=30),confirmed by 75 g OGTT.FPG,HbA1c and blood 1ipid were measured.Serum midkine 1evel was determined by ELlSA in each subject. Results    Serum midkine level were higher in T2DM groups thanin NGT group.The order of serum midkine 1evel from 10W to high were NGT group,NDR group。BDRgroup and PDR group[(0.43±0.29)vs(1.73±

0.25 vs (3.01±1.82) vs (4.82±3.62)pg/ml,p<0.05 or P<0.01].Pearson correlation analysis showed that serum midkine level was positively correlated with duration of DR and UAlb level (r=0.559,0.374;P<0.01).Multiple stepwise regression analysis showed
that duration of DR was an independent influencing factor for serum midkine level (β=0.375,P<0.01).Conclusion    Serum midkine level iS significantly associated with the duration and severity of DR.Midkine may be involved in the progression of DR.Thus there is a close relationship between midkine and DR.
      【Key words】  Serum midkine;Diabetic retinopathy(DR);Diabetes mellitus,type 2

上一篇:总胆红素水平在糖尿病视网膜病变早期诊断中的价值 下一篇:血管内皮细胞生长因子抑制剂在新生血管性青光眼治疗中的作用

相关阅读

    暂时没有相关文章